CliffBio
biologic

Aduhelm

aducanumab-avwa

Loss of exclusivity—loss of exclusivity
CompanyBiogen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAduhelm
Active ingredientaducanumab-avwa
Strength170MG/1.7ML (100MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Biogen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.